Stock CYTO ALTAMIRA THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 03:59:50 2024-07-12 pm EDT 		5-day change 1st Jan Change
1.31 USD -0.76% Intraday chart for Altamira Therapeutics +2.34% -62.36%
Jun. 20 Altamira Therapeutics Ltd. Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management CI
May. 16 Altamira Therapeutics Ltd. Elects Dominik Lysek as Member of Board of Directors CI

Valuation

Fiscal Period: December 2019 2023 2024 2025 2026
Capitalization 1 5.174 1.164 3.129 - -
Enterprise Value (EV) 1 3.789 1.164 3.129 3.129 3.129
P/E ratio -0.69 x -0.37 x -0.3 x -0.41 x -0.73 x
Yield - - - - -
Capitalization / Revenue - - - - 0.7 x
EV / Revenue - - - - 0.7 x
EV / EBITDA -715,778 x - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 8.26 398 2,671 - -
Reference price 2 626.7 2.927 1.171 1.171 1.171
Announcement Date 4/16/20 4/10/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2023 2024 2025 2026
Net sales 1 - - - - 4.476
EBITDA -7.228 - - - -
EBIT 1 -7.259 - -7.846 -10.29 -8.683
Operating Margin - - - - -194%
Earnings before Tax (EBT) 1 -6.826 - -7.84 -10.17 -8.531
Net income 1 -6.632 -3.869 -7.84 -10.17 -8.531
Net margin - - - - -190.61%
EPS 2 -912.0 -7.880 -3.890 -2.890 -1.610
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 4/16/20 4/10/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 - - - - -
EBITDA - - - - -
EBIT -3.152 - - - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income -3.028 - - - -
Net margin - - - - -
EPS 2 -248.0 -2.140 -1.750 -1.520 -1.240
Dividend per Share - - - - -
Announcement Date 4/16/20 - - - -
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position 1.38 - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 3.02 - - - -
Capex / Sales - - - - -
Announcement Date 4/16/20 4/10/24 - - -
1CHF in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.12% 126B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+25.25% 119B
ARGENX SE Stock argenx SE
+25.56% 27.95B
BIONTECH SE Stock BioNTech SE
-19.51% 20.5B
GENMAB A/S Stock Genmab A/S
-14.36% 17.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.63% 16.1B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.67% 14.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.89% 14.84B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.74% 14.38B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYTO Stock
  4. CYTO Stock
  5. Financials Altamira Therapeutics